KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Capital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesChange in ReceivablesExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeSales of Property, Plant and EquipmentSales of Property, Plant and EquipmentShare-based CompensationShare-based CompensationShares IssuedShares Repurchased
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bio-Rad Laboratories (BIO) Cash from Investing Activities (2016 - 2026)

Bio-Rad Laboratories has reported Cash from Investing Activities over the past 18 years, most recently at -$93.2 million for Q1 2026.

  • Quarterly Cash from Investing Activities fell 3313.79% to -$93.2 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was -$285.8 million through Mar 2026, down 150.26% year-over-year, with the annual reading at -$189.7 million for FY2025, 18.41% down from the prior year.
  • Cash from Investing Activities was -$93.2 million for Q1 2026 at Bio-Rad Laboratories, down from -$34.2 million in the prior quarter.
  • Over five years, Cash from Investing Activities peaked at $72.2 million in Q4 2023 and troughed at -$916.1 million in Q1 2022.
  • The 5-year median for Cash from Investing Activities is -$43.1 million (2024), against an average of -$95.9 million.
  • Year-over-year, Cash from Investing Activities surged 223.28% in 2023 and then plummeted 3313.79% in 2026.
  • A 5-year view of Cash from Investing Activities shows it stood at -$58.6 million in 2022, then surged by 223.28% to $72.2 million in 2023, then plummeted by 142.25% to -$30.5 million in 2024, then decreased by 12.13% to -$34.2 million in 2025, then crashed by 172.51% to -$93.2 million in 2026.
  • Per Business Quant, the three most recent readings for BIO's Cash from Investing Activities are -$93.2 million (Q1 2026), -$34.2 million (Q4 2025), and -$43.0 million (Q3 2025).